Efficacy of Irisin Administration on Neurological and Tissue-related Outcomes in Cerebral Ischemia / Reperfusion Injuries; a Scoping Review
Journal of Practical Emergency Medicine,
Vol. 10 No. 1 (2023),
1 January 2023
,
Page e25
https://doi.org/10.22037/jpem.v10i1.42858
Abstract
Background: Evidence indicates the protective role of Irisin on nervous tissue following ischemic events, by preventing the cascades of secondary damage. We conducted this scoping review to summarize what has been discovered so far on the neuroprotective effects of Irisin, with a focus on ischemic stroke.
Methods: Search strategies were designed based on the keywords related to ischemic stroke and Irisin. Next, an extensive search in Medline, Embase, Scopus, and Web of Science was conducted by the end of April 2022. Two researchers independently reviewed the articles and performed the screening of the selected papers according to the inclusion criteria. Finally, the required data were extracted to a checklist designed based on the PRISMA guideline. The “meta” package was used for the meta-analysis, and heterogeneity between studies was assessed using the I2 test.
Results: Pooled data analysis showed that the Irisin administration significantly improved the neurological function following cerebral ischemia / reperfusion injuries (SMD = 3.08; 95% CI: 1.10, 5.06; p<0.0001). Additionally, meta-regression demonstrated that the improvement in neurological function was directly related to the dose of administered Irisin (meta-regression coefficient = 0.03; p = 0.02). Moreover, Irisin administration significantly reduced the volume of infarcted lesions (SMD= -3.14; 95% CI: -4.23, -2.04; p<0.0001), the amount of edema in the brain (SMD= -2.30; 95% CI: -4.07, -0.53; p<0.0001), and the extend of neuronal-cell apoptosis rate (SMD= -4.67; 95% CI: -8.15, -1.19; p<0.0001).
Conclusion: The present study demonstrates that the administration of Irisin in animal models of cerebral ischemia / reperfusion injuries is associated with a significant dose-dependent improvement in neurological function. Due to the limited number of articles, more research on the aim of finding the optimum Irisin dosage is in high demand.
- FNDC5 protein
- Neurological function
- Stroke
- Infarct area
- Motor function
How to Cite
References
2. Kamal N, Sheng S, Xian Y, Matsouaka R, Hill MD, Bhatt DL, et al. Delays in door-to-needle times and their impact on treatment time and outcomes in get with the guidelines-stroke. Stroke. 2017;48(4):946-54.
3. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharmacol Sci. 2014;125(2):125-31.
4. Hultman E, Greenhaff PL. Skeletal muscle energy metabolism and fatigue during intense exercise in man. Sci Prog. 1991;75(298 Pt 3-4):361-70.
5. Polyzos SA, Kountouras J, Shields K, Mantzoros CS. Irisin: a renaissance in metabolism? Metabolism-Clinical and Experimental. 2013;62(8):1037-44.
6. Chen K, Wang K, Wang T. Protective effect of irisin against Alzheimer's disease. Front Psychiatry. 2022;13:967683.
7. Fu J, Li F, Tang Y, Cai L, Zeng C, Yang Y, et al. The emerging role of irisin in cardiovascular diseases. Journal of the American Heart Association. 2021;10(20):e022453.
8. Lourenco MV, Ribeiro FC, Sudo FK, Drummond C, Assunção N, Vanderborght B, et al. Cerebrospinal fluid irisin correlates with amyloid‐β, BDNF, and cognition in Alzheimer's disease. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2020;12(1):e12034.
9. Croll S, Suri C, Compton D, Simmons M, Yancopoulos G, Lindsay R, et al. Brain-derived neurotrophic factor transgenic mice exhibit passive avoidance deficits, increased seizure severity and in vitro hyperexcitability in the hippocampus and entorhinal cortex. Neuroscience. 1999;93(4):1491-506.
10. Asadi Y, Gorjipour F, Behrouzifar S, Vakili A. Irisin peptide protects brain against ischemic injury through reducing apoptosis and enhancing BDNF in a rodent model of stroke. Neurochemical Research. 2018;43(8):1549-60.
11. Hooijmans CR, Rovers MM, de Vries R, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC medical research methodology. 2014;14(1):1-9.
12. Androutsellis-Theotokis A, Leker RR, Soldner F, Hoeppner DJ, Ravin R, Poser SW, et al. Notch signalling regulates stem cell numbers in vitro and in vivo. Nature. 2006;442(7104):823-6.
13. Cao Q, Li P, Lu J, Dheen S, Kaur C, Ling EA. Nuclear factor‐κB/p65 responds to changes in the Notch signaling pathway in murine BV‐2 cells and in amoeboid microglia in postnatal rats treated with the γ‐secretase complex blocker DAPT. Journal of neuroscience research. 2010;88(12):2701-14.
14. Catanese L, Tarsia J, Fisher M. Acute ischemic stroke therapy overview. Circulation research. 2017;120(3):541-58.
15. Colaianni G, Cuscito C, Mongelli T, Pignataro P, Buccoliero C, Liu P, et al. The myokine irisin increases cortical bone mass. Proceedings of the National Academy of Sciences. 2015;112(39):12157-62.
16. Begni V, Riva MA, Cattaneo A. Cellular and molecular mechanisms of the brain-derived neurotrophic factor in physiological and pathological conditions. Clinical Science. 2017;131(2):123-38.
17. Candelario-Jalil E, Yang Y, Rosenberg G. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience. 2009;158(3):983-94.
18. Asahi M, Wang X, Mori T, Sumii T, Jung J-C, Moskowitz MA, et al. Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. Journal of neuroscience. 2001;21(19):7724-32.
19. Hu Q, Chen C, Yan J, Yang X, Shi X, Zhao J, et al. Therapeutic application of gene silencing MMP-9 in a middle cerebral artery occlusion-induced focal ischemia rat model. Experimental neurology. 2009;216(1):35-46.
20. Yu Q, Li G, Ding Q, Tao L, Li J, Sun L, et al. Irisin protects brain against ischemia/reperfusion injury through suppressing TLR4/MyD88 pathway. Cerebrovascular Diseases. 2020;49(4):346-54.
21. Jayaraj RL, Azimullah S, Beiram R, Jalal FY, Rosenberg GA. Neuroinflammation: friend and foe for ischemic stroke. Journal of neuroinflammation. 2019;16(1):1-24.
22. Wang J, He G-Z, Wang Y-K, Zhu Q-K, Chen W, Guo T. TLR4-HMGB1-, MyD88-and TRIF-dependent signaling in mouse intestinal ischemia/reperfusion injury. World Journal of Gastroenterology: WJG. 2015;21(27):8314.
23. Gao Y, Fang X, Tong Y, Liu Y, Zhang B. TLR4-mediated MyD88-dependent signaling pathway is activated by cerebral ischemia–reperfusion in cortex in mice. Biomedicine & Pharmacotherapy. 2009;63(6):442-50.
24. Maak S, Norheim F, Drevon CA, Erickson HP. Progress and Challenges in the Biology of FNDC5 and Irisin. Endocrine reviews. 2021;42(4):436-56.
25. Albrecht E, Norheim F, Thiede B, Holen T, Ohashi T, Schering L, et al. Irisin–a myth rather than an exercise-inducible myokine. Scientific reports. 2015;5(1):1-10.
- Abstract Viewed: 592 times
- pdf Downloaded: 225 times
